1. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party;G J Schuurhuis;Blood,2018
2. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts;N J Short;American Journal of Hematology,2019
3. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation;Z Wang;Int. J. Lab. Hematol,2019
4. Droplet digital PCR improves IG-/TR-based MRD risk definition in childhood B-cell precursor acute lymphoblastic leukemia;I;HemaSphere
5. Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies;R S�nchez;International Journal of Molecular Sciences,2019